Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01274637 · ClinicalTrials.gov registry record · Phase 3
PROSPER: PostpaRtum PrOphylaxiS for PE Randomized Control Trial Pilot
A Phase 3 study, sponsored by Ottawa Hospital Research Institute.
- Completed
- Registry status
- Phase 3
- Development phase
- 62
- Enrollment target
NCT01274637 is a Phase 3 study that has completed, run by Ottawa Hospital Research Institute. The registered enrollment target is 62 participants.
The verdict
NCT01274637, a Phase 3 study, has completed, sponsored by Ottawa Hospital Research Institute.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 62 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if it is feasible to conduct a multi-center randomized trial to determine whether a blood thinner, low-molecular-weight-heparin (LMWH), is effective at preventing blood clots, thromboembolism (VTE), in postpartum women at risk.
Interventions
- DRUG Dalteparin Sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2011-03 |
| Est. Completion | 2014-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01274637
The ClinicalTrials.gov registry entry for NCT01274637 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ottawa Hospital Research Institute, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dalteparin Sodium is the first listed.
NCT01274637 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01274637 about?
NCT01274637 is a clinical study titled "PROSPER: PostpaRtum PrOphylaxiS for PE Randomized Control Trial Pilot". The purpose of this study is to determine if it is feasible to conduct a multi-center randomized trial to determine whether a blood thinner, low-molecular-weight-heparin (LMWH), is effective at preventing blood clots, thromboembolism (VTE), in postpartum women at risk.
What is the current status of trial NCT01274637?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 62 participants. The study started on 2011-03. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01274637?
The interventions under investigation include: Dalteparin Sodium (DRUG).
Who is sponsoring clinical trial NCT01274637?
This trial is sponsored by Ottawa Hospital Research Institute, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.